ACRS 250516 1.00C(ACRS250516C1000) Stock Price Today

US OptionsDetailed Quotes

ACRS250516C1000

Watchlist

0.36
-0.04-10.00%

15min DelayTrading May 9 12:30 ET

0.36High0.36Low

Intraday

5D
Daily

News

Aclaris Therapeutics Price Target Lowered to $9 From $15 at Scotiabank
TipRanksMay 9 10:16 ET
Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series
GlobeNewswireMay 9 07:00 ET
Aclaris Therapeutics | 10-Q: Quarterly report
SECMay 8 16:31 ET · Announcements
Aclaris Therapeutics Reports Q1 EPS (12c), Consensus (12c)
TipRanksMay 8 07:34 ET
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
SECMay 8 07:16 ET · Announcements
Express News | Aclaris Therapeutics Q1 Net Income USD -15.085 Million Vs. IBES Estimate USD -13.3 Million
ReutersMay 8 06:50 ET

Comments

Trytosaveabit

May 8 19:22

note the dates

$Aclaris Therapeutics (ACRS.US)$ ATI-2138: Investigational oral covalent ITK/JAK3 inhibitor
● Top Line Results from Phase 2a Trial in AD Expected in June 2025: Dosing is complete in the single arm Phase 2a open-label trial of ATI-2138 designed to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in patients with moderate-to-severe AD. The Company expects to report top line results in June 2025. Potential target indications under consi...

Growth lover

May 1 02:12

$Aclaris Therapeutics (ACRS.US)$ 13 G FILLED 🚀

This_Guy

Apr 22 19:07

$Aclaris Therapeutics (ACRS.US)$
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2

Trytosaveabit

Apr 22 19:04

news

$Aclaris Therapeutics (ACRS.US)$ Reuters· 4 mins ago
Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody